Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase EARLY_PHASE1 × Lapatinib × Genitourinary × Clear all

Phase

Phase 2 5 Phase 1 3 Phase EARLY_PHASE1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 2 Tumor-Agnostic 1 Genitourinary 1 CNS 1

Conditions

Urinary Bladder Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 11 gallium 68 PSMA-11 7 Fluorodeoxyglucose F18 4 Specimen Handling 3 Positron Emission Tomography Computed Tomography 3 Biopsy 3 68Ga-DKFZ-PSMA-11 3 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 3 pembrolizumab 2 pazopanib 2 bicalutamide 2 atezolizumab 2 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 2 X-Rays 2 Standard of Care 2 Radiation 2 Positron-Emission Tomography 2 Paclitaxel 2 Nivolumab 2 Metastasectomy 2 Ipilimumab 2 Immunoglobulin G 2 Hydroxychloroquine 2 HhAntag691 2 Disulfides 2 Cyclophosphamide 2 Cryosurgery 2 Carboplatin 2 Bevacizumab 2 Abiraterone Acetate 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01245660 2013-01-11

LAPAINBLAD

University Hospital, Bordeaux

Phase EARLY_PHASE1 Terminated

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡